Learn More
Regulation of osteoclastic activity is critical for understanding bone loss associated with the postmenopausal period. In vitro and animal studies have revealed the role of OPG as a decoy receptor that neutralizes the effect of RANKL on the differentiation and activation of osteoclasts. However, the role of the OPG-RANKL system in postmenopausal(More)
OBJECTIVE Bisphosphonates are potent inhibitors of bone resorption that are used as effective therapeutic agents for the management of osteoporosis and other bone diseases. The osteoprotegerin (OPG)-receptor activator of nuclear factor kappaB (RANKL) system plays an important role in the regulation of bone metabolism and vascular biology. The effects of(More)
Lysosomal α-galactosidase A (α-Gal) is the enzyme deficient in Fabry disease (FD), an X-linked glycosphingolipidosis caused by pathogenic mutations affecting the GLA gene. The early-onset, multi-systemic FD classical phenotype is associated with absent or severe enzyme deficiency, as measured by in vitro assays, but patients with higher levels of residual(More)
  • 1